Phone: 203-315-4000
Fax: 203-315-4002
Website: http://www.ipd-discovery.com

Contact(s)
Gordon P. Polley, Chairman - gordon.polley@ipd-discovery.com

General Information
IPD was founded in 1995 and, with the creation of the Institute for Diabetes Discovery shortly after its founding, undertook discovery research to develop pharmaceuticals for the treatment of diabetes and obesity. That research has led to an aldose reductase inhibitor ("Lidorestat," now in Phase II clinical trials), and a protein tyrosine phosphatase inhibitor ("PTP1b inhibitor," expected to enter clinical trials in early 2006). IDD intends to license each of these products to pharmaceutical companies who would complete clinical development and undertake worldwide marketing of the products. The Institute for Bioanalytics was formed in 1997, with the objective of providing bioanalytical method development services to the pharmaceutical industry.

Research Activities
IDD maintains state-of-the-art drug discovery facilities, including biochemistry, synthetic chemistry, comparative medicine, and pharmacokinetics groups, supported by high throughput screening, combinatorial chemistry and mass spectrometry.

Other Information
Ownership: Private
CT Employees: 75

Back